# Merck Sharp & Dohme LLC: Phase 3 study started recruiting, 802 planned (Ovarian Cancer, Ovarian Neoplasms)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) |
| NCT ID | NCT07776691 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Ovarian Cancer; Ovarian Neoplasms; Peritoneal Cancer; Fallopian Tube Cancer |
| Intervention types | biological, drug |
| Target enrollment | 802 |
| Site countries | United States, Israel, South Korea, Taiwan |
| Posted | 2026-08-20 |
| Planned start | 2026-09-18 |
| Event | Started recruiting |
| Event date | 2026-09-18 |
| Last update posted | 2026-10-29 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 3: multi-site, larger budget.
- 802 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07776691). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.